Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02649855 | Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05133440 | A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05156268 | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | completed | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06059014 | Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer(PRadR) | completed | Phase 1 / Phase 2 | 6 | Centre Leon BerardOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04925648 | Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction(PICASSO) | completed | Phase 2 | 4 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04523207 | A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | completed | Phase 2 | 108 | Janssen Research & Development, LLCINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06138496 | Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | completed | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT00814021 | Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain | completed | Phase 2 | 21 | Institut Claudius RegaudOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01902680 | Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.(CURIEFOCALE) | completed | Phase 2 | 18 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02225704 | Radium-223 in Combination With Enzalutamide | completed | Phase 2 | 45 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02772588 | AASUR in High Risk Prostate Cancer | completed | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03694262 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)(EndoBARR) | completed | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03612791 | Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab(ATEZOLACC) | completed | Phase 2 | 189 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07505615 | A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer(VG-INFUSE Tria) | completed | Phase 1 / Phase 2 | 20 | Ding-Wei YeOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03496805 | Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy | completed | Phase 2 | 106 | Wake Forest University Health SciencesOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05226117 | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | completed | Phase 2 | 44 | IRCCS San RaffaeleOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03617679 | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | completed | Phase 2 | 79 | University of Colorado, DenverOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT02690558 | Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy | completed | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | completed | Phase 2 | 92 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT01303094 | Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma(T-DIS) | completed | Phase 2 | 53 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04300647 | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer(SKYSCRAPER-04) | completed | Phase 2 | 172 | Hoffmann-La RocheINDUSTRY | 17 | Mar 12, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02867956 | Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04341883 | Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | completed | Phase 1 / Phase 2 | 224 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT00160979 | Transrectal Tumour Oxygen - US Army | completed | Phase 2 | 186 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT01616875 | Bristol Bladder Trial | completed | Phase 2 | 28 | University Hospitals Bristol and Weston NHS Foundation TrustOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05008900 | Timing of Post-prostatectomy PSMA Imaging(TOPP) | completed | Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04288687 | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | completed | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT01409200 | Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | completed | Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04443062 | Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer(Bullseye) | completed | Phase 2 | 58 | Radboud University Medical CenterOTHER | 2 | Feb 27, 2026 | clinicaltrials |
| NCT06056791 | Study of INKmune in Patients With mCRPC (CaRe Prostate)(CaRe) | completed | Phase 1 / Phase 2 | 12 | Inmune Bio, Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT01314118 | IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen | completed | Phase 2 | 131 | Janssen Biotech, Inc.INDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT03568188 | Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer(FOCALE) | completed | Phase 2 | 174 | Hospices Civils de LyonOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04172675 | A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) | completed | Phase 2 | 107 | Janssen Research & Development, LLCINDUSTRY | 17 | Feb 24, 2026 | clinicaltrials |
| NCT00809991 | Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate | completed | Phase 2 | 91 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03421782 | Fatigue Interventions in Cancer (Exercise Intervention) | completed | Phase 2 | 126 | University of UtahOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06661902 | Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial(BURN) | completed | Phase 1 / Phase 2 | 350 | University of WashingtonOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT01543659 | Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 77 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT02274779 | Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer(OLIGOPELVIS) | completed | Phase 2 | 74 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT01517451 | Radiation and Androgen Ablation for Prostate Cancer | completed | Phase 1 / Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04089189 | Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer(SABRINA) | completed | Phase 2 | 93 | Impact Therapeutics, Inc.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03338790 | An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer(CheckMate 9KD) | completed | Phase 2 | 292 | Bristol-Myers SquibbINDUSTRY | 11 | Jan 27, 2026 | clinicaltrials |
| NCT03565835 | Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | completed | Phase 2 | 31 | Montefiore Medical CenterOTHER | 1 | Jan 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 29, 2026source: clinicaltrials